Medicare & Semaglutide: What's Typically Covered (and What Isn't)

Navigating the complexities of Medicare coverage for popular GLP-1 medications like Ozempic, Wegovy, and Rybelsus can be a significant challenge for beneficiaries. While these drugs offer proven benefits for type 2 diabetes and cardiovascular health, their high cost and specific FDA-approved uses create a confusing landscape of what is and isn't covered. A long-standing federal law prohibits Medicare from paying for drugs when prescribed solely for weight loss, adding another layer of complexity.

This guide provides a clear, evidence-based overview of what Medicare typically covers, what it excludes, the crucial role of prior authorization, and the major changes coming in 2026 and 2027 that will expand access for millions.

By | Medically Reviewed by Dr. John Doe, PharmD | Last Updated:

Key Takeaways

  • Coverage Depends on Indication: Medicare Part D generally covers GLP-1s like Ozempic and Rybelsus for type 2 diabetes and Wegovy for reducing cardiovascular risk in patients with established heart disease, but not for weight loss alone.
  • Prior Authorization is Now Standard: As of 2024, over 83% of Medicare Part D plans require prior authorization for these drugs, a sharp increase from under 25% in mid-2023, to ensure they are used for covered indications.
  • Big Changes Coming in 2026-2027: The new CMS BALANCE model will begin offering coverage for GLP-1s for weight management. A temporary payment demonstration starts in July 2026, allowing eligible beneficiaries to pay a $50 monthly copay, with full Part D plan participation beginning in January 2027.
  • Out-of-Pocket Costs Vary: Even with coverage, beneficiaries face deductibles and coinsurance. In 2026, the Part D deductible is $615, and the annual out-of-pocket maximum is $2,100.

Quick Answer: Does Medicare Cover Ozempic, Wegovy, or Semaglutide?

Yes, but only for specific, FDA-approved medical conditions. Medicare Part D plans will cover semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) if your doctor prescribes it to treat type 2 diabetes or to reduce the risk of heart attack and stroke in patients with known cardiovascular disease. However, federal law explicitly prohibits Medicare from covering medications when they are prescribed only for chronic weight management. This is expected to change starting in July 2026 with a new payment demonstration program, but until then, coverage for weight loss is not available.

Medical Disclaimer

This guide is for informational purposes only and does not constitute medical advice. Coverage policies change frequently. Always consult with your healthcare provider and your specific Medicare Part D plan to confirm your benefits and costs.

What Medicare Covers Today: A Tale of Two Indications

The central issue determining Medicare coverage for semaglutide is the reason for the prescription. The Social Security Act specifically excludes drugs used for "anorexia, weight loss, or weight gain" from Part D coverage. This statutory exclusion is the primary barrier to coverage for obesity treatment.

However, when these same drugs are approved for other conditions, Medicare can and does cover them. This creates two distinct coverage pathways:

Covered Indication Not Covered Indication
Type 2 Diabetes Mellitus Chronic Weight Management
Cardiovascular Risk Reduction General Obesity

Covered: Type 2 Diabetes & Cardiovascular Health

Medicare Part D provides robust coverage for GLP-1 medications when used for their approved non-weight loss indications. As of early 2026, here is what is typically covered:

  • Ozempic® (injectable semaglutide): Covered for adults with type 2 diabetes to improve glycemic control and to reduce the risk of major adverse cardiovascular events (like heart attack or stroke) in those with established cardiovascular disease.
  • Rybelsus® (oral semaglutide): Covered for adults with type 2 diabetes to improve glycemic control.
  • Wegovy® (injectable semaglutide): Covered to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. This indication was approved by the FDA in March 2024, opening a critical access pathway for many Medicare beneficiaries.
  • Mounjaro® (tirzepatide): A similar GIP/GLP-1 drug, is also widely covered for type 2 diabetes.

Not Covered: Chronic Weight Management

If a doctor prescribes Wegovy, Ozempic, or any other GLP-1 solely for the purpose of helping a patient lose weight, Medicare Part D is legally barred from paying for it. This remains the case even though Wegovy is FDA-approved for chronic weight management. The statutory exclusion overrides the FDA's approval in the context of Medicare payment.

The Rise of Prior Authorization: A Necessary Hurdle

Given the dual uses of these drugs, how do Part D plans ensure they are only paying for the covered indications? The answer is prior authorization (PA).

In response to soaring demand and high costs, Part D plans have rapidly implemented PA requirements. A study in JAMA Network Open found that while fewer than 25% of plans required PA for these drugs in mid-2023, that number skyrocketed to over 83% by mid-2024. [1]

This means that before the pharmacy can dispense your medication, your doctor must submit documentation to the insurance plan proving that you meet the clinical criteria for a covered use. This typically involves providing:

  • A diagnosis of type 2 diabetes (e.g., with supporting A1c lab values).
  • A diagnosis of established cardiovascular disease (e.g., a history of heart attack or stroke).
  • Documentation that the prescription is for one of these specific, covered conditions.

While this adds an administrative step, it is a crucial gatekeeping mechanism that allows plans to adhere to Medicare rules while still providing access for medically necessary, covered treatments.

The Future of Coverage: The BALANCE Model and 2026/2027 Changes

Recognizing the public health importance of treating obesity, the Centers for Medicare & Medicaid Services (CMS) has introduced a new program to circumvent the statutory payment exclusion.

The BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model is a voluntary payment model designed to expand access to GLP-1s for weight management. [2]

Here’s how it will work:

  1. July 2026: The Payment Demonstration Bridge: A short-term "payment demonstration" will launch. This program will operate outside of the standard Part D benefit. Eligible Medicare beneficiaries who are enrolled in a Part D plan will be able to get certain GLP-1s for weight loss for a $50 monthly copay. This is a temporary bridge to the full model.
  2. January 2027: Full BALANCE Model Integration: Part D plans can voluntarily choose to participate in the full BALANCE model. For those that do, GLP-1s for weight management will be integrated into the formulary. Beneficiaries will still be responsible for their plan's deductible and other cost-sharing, but the program aims to make these drugs more affordable.

This is a landmark change, but it's important to note that coverage is not guaranteed. It will depend on which drug manufacturers and Part D plans decide to participate in this voluntary model.

Understanding Your Out-of-Pocket Costs

Even when a GLP-1 is covered by your Part D plan, you will likely have out-of-pocket expenses. The standard Part D benefit has several phases:

2026 Part D Cost Phase What You Pay
Deductible You pay 100% of drug costs until you meet the $615 annual deductible.
Initial Coverage After the deductible, you pay a 25% coinsurance on the cost of the drug.
Catastrophic Coverage Once your total out-of-pocket spending reaches $2,100, you pay $0 for the rest of the year.

For a high-cost drug like Ozempic or Wegovy (with list prices often exceeding $1,000 per month), a 25% coinsurance can still be several hundred dollars per month. Beneficiaries will likely reach the $2,100 catastrophic cap quickly, after which their costs will drop to zero.

Frequently Asked Questions

Why does my friend have coverage for Ozempic for weight loss, but I don't?

Your friend likely has commercial insurance through an employer, not Medicare. Many commercial plans do cover weight loss medications, although they often still require prior authorization.

Will the BALANCE model cover all GLP-1 drugs?

Not necessarily. Coverage will depend on which drug manufacturers agree to participate and negotiate pricing with CMS. The specific drugs included will be announced closer to the program's launch.

If my doctor says it's medically necessary, why won't Medicare pay?

Under Medicare law, "medical necessity" is not the only factor. The law contains specific exclusions, and the exclusion for weight loss drugs is a primary example. The new BALANCE model is a specific workaround to this legal constraint.

What can I do if I can't afford my medication?

If you have a covered indication but still face high costs, you may qualify for the Medicare Part D Low-Income Subsidy (LIS), also known as Extra Help. This program can significantly lower your premiums and copayments. You can also check for Patient Assistance Programs (PAPs) offered by the drug manufacturers.

References

  1. Liu, X., et al. (2025). Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans. JAMA Network Open. https://pmc.ncbi.nlm.nih.gov/articles/PMC12397888/
  2. Centers for Medicare & Medicaid Services. (2026). BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model. https://www.cms.gov/priorities/innovation/innovation-models/balance
  3. KFF. (2026). Recent Trends in GLP-1 Use and Spending in Medicare. https://www.kff.org/medicare/recent-trends-in-glp-1-use-and-spending-in-medicare/
  4. AARP. (2026). When Will Medicare Cover Ozempic, Other Weight-Loss Drugs? https://www.aarp.org/medicare/faq/does-medicare-cover-ozempic-weight-loss-drugs/
  5. Social Security Administration. Social Security Act §1862. https://www.ssa.gov/OP_Home/ssact/title18/1862.htm
  6. U.S. Food & Drug Administration. (2024). FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or